Hope on the Horizon: Gene Therapy Offers New Life for Children with Canavan Disease
A groundbreaking gene therapy trial in the United States is offering a beacon of hope for children diagnosed with Canavan disease, a rare and devastating genetic disorder. An Irish child is among the first to receive the experimental treatment, administered at Dayton Children’s Hospital in Ohio, with early results showing promising signs of improvement.
Understanding Canavan Disease: A Race Against Time
Canavan disease is caused by a faulty enzyme, aspartoacyclase (Aspa), leading to a toxic buildup of N-acetyl-aspartic acid (NAA) in the brain. This buildup damages the myelin, the protective insulation around nerve cells, disrupting crucial nerve signals. Babies often appear healthy at birth, but typically begin to experience developmental delays as their brains deteriorate. Symptoms can include poor head control, listlessness, feeding difficulties and seizures. Without treatment, the condition is often fatal before the age of 10.
The Challenge of Diagnosis and the Search for Treatment
Previously, diagnosing Canavan disease was a lengthy process, often delaying access to any potential care. Dr. Lee Coffey, a lecturer and molecular biologist at South East Technological University in Waterford, experienced this firsthand when his brother’s children received the diagnosis. “It took months of persistence for them to finally find out, and in the meantime the symptoms were accumulating,” Coffey recalls, noting the family had to pay privately for genetic sequencing.
For years, families facing this diagnosis were told there were no treatment options. This spurred research into gene therapy, aiming to deliver a working copy of the gene responsible for producing the Aspa enzyme directly into brain cells.
A Novel Approach to Gene Therapy
Researchers, including Prof. Paola Leone at Rowan-Virtua College of Medicine and Science in New Jersey, have been working for decades to develop a gene therapy for Canavan disease. Leone’s work, beginning with a small study in the 1990s, focused on using viruses to deliver the necessary gene. “Canavan found me, rather than me finding Canavan,” she recalls, describing how parents of newly diagnosed children sought her out even when funding was limited.
The therapy being trialed in Ohio involves delivering the gene via a catheter directly into the baby’s brain. Neurosurgeon Dr. Rob Lober, who performed the procedure on the Irish infant, reported positive early signs. “Within the first month she was laughing in our clinic and there were changes that the family could see,” he says. Brain scans also showed reduced swelling.
Early Results and Future Prospects
Initial results, published in the journal Nature Medicine last year, included data from eight children, including the Irish patient. The family, who have requested anonymity, shared their optimism, stating, “While it is still early days, we are already beginning to see some positive impacts of the treatment and One can say without doubt that we have a happier, more content little baby.”
Dr. Lober emphasized the experimental nature of the treatment. “Our small community hospital probably has the most experience in the world in Canavan disease, since we’ve seen so many patients. But you don’t want to supply false hope. This is still an experiment.” Researchers are still working to determine the optimal dosage and the age at which the therapy is most effective.
Beyond Canavan: Expanding the Potential of Gene Therapy
The advancements in gene therapy for Canavan disease have broader implications for the treatment of other rare genetic disorders, known as leukodystrophies, which also affect the myelin sheath. The techniques developed for Canavan may offer a pathway to therapies for these related conditions.
The Road to Approval and Accessibility
Myrtelle, the biotech company leading the trial, plans to submit a biologics license application to the US Food and Drug Administration this year, with potential approval anticipated in 2027. Jordana Holovach, head of communications and community at Myrtelle, founded a non-profit organization to support research and raise awareness after her own child was diagnosed with Canavan disease.
Frequently Asked Questions
- What is Canavan disease? A rare genetic disorder that damages the brain by causing a buildup of a toxic compound.
- What are the symptoms of Canavan disease? Developmental delays, poor head control, listlessness, feeding difficulties, and seizures.
- Is there a cure for Canavan disease? Currently, there is no cure, but gene therapy is showing promising results in clinical trials.
- How does gene therapy work for Canavan disease? It delivers a working copy of the faulty gene into brain cells, allowing them to produce the necessary enzyme to clear the toxic buildup.
Pro Tip: Early diagnosis is crucial for maximizing the potential benefits of gene therapy. If you suspect your child may have Canavan disease, seek genetic testing immediately.
Do you have questions about Canavan disease or gene therapy? Share your thoughts in the comments below!
Explore more articles on rare genetic disorders here.
